Stock futures were slightly lower on Thursday, Sept. 14, putting markets on track to slip from records set a day earlier.
Dow Jones Industrial Average futures were down 0.02%, S&P 500 futures fell 0.1%, and Nasdaq futures declined 0.21%.
A surge in crude oil prices, and energy names, led stocks to fresh all-time highs on Wednesday, Sept. 13, their second record-setting day in a row. The Dow, S&P 500, and Nasdaq each notched all-time highs with just small gains for their second day in a row. Any gains on Thursday would put benchmark indexes at records for their third day in a row.
U.S. consumer prices for August rose at a slightly faster pace than expected. The Consumer Price Index increased by 0.4%, four times the pace in July, and 10 basis points higher than expected. Core prices, excluding food and gas, climbed 0.2% and met consensus. Core prices over the past 12 months increased 1.7%, a flat reading from a month earlier.
U.S. producer prices, released a day earlier, rose at a slower pace than anticipated with a large bulk of the rise attributed to higher gas prices.
Inflation numbers out this week could give the Federal Reserve pause, especially as the inflation rate struggles to reach the Fed's 2% target. Recent weak readings on inflation have been characterized by Fed members as "transitory." Producer and consumer prices for August will factor into the Fed's next policy decision.
The Federal Open Market Committee, the decision-making branch of the central bank, will meet for two days beginning on Tuesday, Sept. 19. An announcement and updated forecasts will be released on Wednesday, Sept. 20, followed by press comments from Fed Chair Janet Yellen.
If you'd like to receive our daily "5 Things You Must Know" newsletter, please register here.
Economic data picks up on Friday, Sept. 15. Retail sales and industrial production for August, the Empire State Manufacturing Survey for September, a preliminary reading for consumer sentiment for September, and business inventories for July will be released throughout Friday morning.
The number of new claims for unemployment benefits fell in the past week, though the four-week average spiked. Initial weekly jobless claims fell by 13,000 to 284,000. The less volatile four-week average increased 13,000 to 263,250. Jobless claims data is often erratic in the aftermath of hurricanes and other natural disasters that disrupt employment.
Crude oil prices continued to climb on Thursday after settling at their highest level in five weeks a day earlier. Wednesday's rally kicked off on signs of reduced global production sparked a rally in crude oil on Wednesday. Global oil supplies have hit a snag in recent weeks as Hurricane Harvey limited output in the U.S. and declining activity in the Middle East helped the Organization of Petroleum Exporting Countries keep to a previous deal to limit production.
West Texas Intermediate crude was up 1.2% to $49.88 a barrel on Thursday.
Equifax Inc. (EFX) - Get Report has blamed a bug in its web-server software for allowing hackers to access a massive chunk of sensitive data. Last week, Equifax disclosed that a security breach had compromised millions of people's private data with estimates that more than 143 million people had had their names, Social Security numbers, birth dates and drivers license numbers exposed. The credit-reporting agency said it has been "intensely investigating the scope of the intrusion" since it became aware of the problem.
Shares of Tenet Healthcare Corp. (THC) - Get Report were up 7.7% in premarket trading on Thursday after a report said the Dallas-based healthcare services company was exploring options related to its future, including the possible sale of the company. Tenet announced last month that it would replace Chairman and CEO Trevor Fetter as director and CEO amid pressure from Glenview Capital Management, an activist investor who owns a 17.8% stake in the company.
Tenet, one of the largest hospital companies in the U.S., has hired banking advisers to consider a number of possibilities, The Wall Street Journal reported. The process was still in an early phase, and there was no guarantee a deal would come about, according to the Journal.
Pfizer Inc. (PFE) - Get Report rose slightly on Thursday after one of its cancer drugs met a primary endpoint in a late-stage clinical trial. Cancer drug Xtandi, when combined with prostate cancer therapy, improved metastasis-free survival in patients with non-metastatic castration-resistant prostate cancer. The trial was conducted with Astellas Pharma Inc. (ALPMF) . The drug is already approved by the Food and Drug Administration for metastatic castration-resistant prostate cancer.
Updated from 7:46 a.m. ET, Sept. 14.
More of What's Trending on TheStreet: